We could not find any results for:
Make sure your spelling is correct or try broadening your search.
Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.
| Share Name | Share Symbol | Market | Type |
|---|---|---|---|
| Inovio Pharmaceuticals Inc New | NASDAQ:INO | NASDAQ | Common Stock |
| Price Change | % Change | Share Price | Bid Price | Offer Price | High Price | Low Price | Open Price | Shares Traded | Last Trade | |
|---|---|---|---|---|---|---|---|---|---|---|
| -0.79 | -6.18% | 12.00 | 11.80 | 11.99 | 12.62 | 11.81 | 12.62 | 414,844 | 01:00:00 |
From May 2019 to May 2024
By Stephen Nakrosis
Shares of Inovio Pharmaceuticals Inc. (INO) are falling in Tuesday's after-hours action, following an announcement by the company that it was informed AstraZeneca plans to discontinue activities on research collaboration programs from an August 7, 2015, agreement, with the exception of MEDI0457.
At 5:49 p.m. ET, Inovio shares had lost 6.69% to trade at $2.92. Inovio's shares lost ground in the day's regular trading session as well, finishing 3.68% lower to close at $3.14 per share.
Inovio said it received notification from MedImmune Limited about the decision. The company also said AstraZeneca will continue to "evaluate MEDI0457, in combination with its PD-L1 checkpoint inhibitor, durvalumab, in multiple Phase 2 clinical trials in patients with cancers associated with human papillomavirus, or HPV."
--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com
(END) Dow Jones Newswires
May 28, 2019 18:22 ET (22:22 GMT)
Copyright (c) 2019 Dow Jones & Company, Inc.
1 Year Inovio Pharmaceuticals Chart |
1 Month Inovio Pharmaceuticals Chart |
It looks like you are not logged in. Click the button below to log in and keep track of your recent history.
Support: +44 (0) 203 8794 460 | support@advfn.com
By accessing the services available at ADVFN you are agreeing to be bound by ADVFN's Terms & Conditions
Hot Features
Premium
